INC completes new CEO succession plan, promotes new execs

INC Research ($INCR) has seen through its plan of transitioning its chief exec of three years, Jamie Macdonald, from the top seat as the CRO also promotes two new execs to its leadership team. 

INC announced back in July that J. Macdonald would be stepping down and replaced by a new Macdonald, Alistair, who this week becomes its new chief. He will give up his former COO role, which will now be taken over by Dr. Michael Gibertini, who had served as the company’s president of clinical development.

As part of the shifts at the top, Tara Fitzgerald, EVP of biometrics, has become the new president of clinical development services. 

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

J. Macdonald will stay on in a transitional role to help out the new CEO until the end of February next year, the CRO said in a statement.

"Michael and Tara both bring experienced leadership, extensive industry and in-depth organizational knowledge and a strategic vision to help guide the future growth and success of INC Research," said A. Macdonald.

“As president, clinical development, Michael has continued to grow and build on INC’s therapeutic expertise as a key differentiator while enhancing our scientific focus to deliver truly innovative clinical development solutions for customers.

“Tara is a proven leader who has delivered exceptional results during her tenure with INC, guiding our biometrics business to deliver consistently strong performance while also providing senior-level leadership for numerous other business-critical initiatives. We look forward to her continued leadership in further optimizing our overall delivery while driving growth across our key value chains.”

He added that he was “thrilled” to take on the CEO role “at this exciting time in our growth.”

INC, which has a market cap of $2.49 billion, was marginally up this morning on the news by 0.1%. 

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.